Answers are grounded in this paper and cite their sources.
Physicians who manage patients with chronic liver diseases in Canada require routine assessment of liver fibrosis stage. Although biopsy remains the primary diagnostic tool for almost one-half of respondents, noninvasive methods, particularly Fibroscan, have significantly reduced the need for liver biopsy in Canada. Limitations in access to and availability of the noninvasive methods represent a significant barrier. Finally, there is a need for clinical guidelines and a better reimbursement policy to implement noninvasive tools to assess liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Sebastiani et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: